Literature DB >> 15111692

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis.

M P Sormani1, M Rovaris, P Valsasina, J S Wolinsky, G Comi, M Filippi.   

Abstract

The measurement errors associated with two techniques for brain atrophy assessment in multiple sclerosis (MS) were estimated. The measurement error of a semiautomated, nonnormalized technique with partial brain coverage was about twofold higher than that of a fully automated, normalized technique with full brain coverage (Structural Image Evaluation of Normalized Atrophy software [SIENA]). As shown by the analysis of data from a clinical trial of glatiramer acetate, the use of SIENA increases the study power to detect a treatment effect on brain volume changes in MS patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15111692     DOI: 10.1212/01.wnl.0000120663.85143.b3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.

Authors:  Robert A Bermel; Srinivas R Puli; Richard A Rudick; Bianca Weinstock-Guttman; Elizabeth Fisher; Frederick E Munschauer; Rohit Bakshi
Journal:  Arch Neurol       Date:  2005-09

Review 2.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

3.  Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.

Authors:  D R Altmann; B Jasperse; F Barkhof; K Beckmann; M Filippi; L D Kappos; P Molyneux; C H Polman; C Pozzilli; A J Thompson; K Wagner; T A Yousry; D H Miller
Journal:  Neurology       Date:  2008-11-12       Impact factor: 9.910

Review 4.  Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

Authors:  Angela Vidal-Jordana; Jaume Sastre-Garriga; Alex Rovira; Xavier Montalban
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

Review 5.  Neuroimaging in multiple sclerosis: neurotherapeutic implications.

Authors:  Nancy L Sicotte
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

6.  Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year.

Authors:  D S Adnan Majid; Diederick Stoffers; Sarah Sheldon; Samar Hamza; Wesley K Thompson; Jody Goldstein; Jody Corey-Bloom; Adam R Aron
Journal:  Mov Disord       Date:  2011-04-11       Impact factor: 10.338

7.  Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study.

Authors:  D Stoffers; S Sheldon; J M Kuperman; J Goldstein; J Corey-Bloom; A R Aron
Journal:  Neurology       Date:  2010-04-13       Impact factor: 9.910

Review 8.  Clinical relevance of brain volume measures in multiple sclerosis.

Authors:  Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 9.  Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.

Authors:  Hans-Peter Hartung; Bernd C Kieseier; Bernhard Hemmer
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

10.  Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

Authors:  D L Arnold; D Campagnolo; H Panitch; A Bar-Or; J Dunn; M S Freedman; S K Gazda; T Vollmer
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.